ChemGenex Pharmaceuticals Limited Teams With MolecularMD To Identify CML Patients With The T315I Drug Resistance Mutation For Phase 2/3 Clinical Trial Of Ceflatonin(R)

MELBOURNE, Australia, & MENLO PARK, Calif.--(BUSINESS WIRE)--June 26, 2006--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) today announced an alliance with MolecularMD, Inc., a leading provider of molecular diagnostic services, including drug resistance mutation screening for chronic myeloid leukemia (CML) patients. The two companies will work together to identify CML patients with the T315I bcr-abl mutation who may be candidates for participation in ChemGenex's phase 2/3 study of Ceflatonin®, in CML patients with this mutation.